Anti-BRAF/MEK therapies (i.e., dabrafenib/trametinib or encorafenib/binimetinib) improve survival for Class I BRAF-mutant NSCLC and are recommended for frontline use by clinical guidelines (12–14). This evidence concerns the gene BRAF and non-small cell lung carcinoma.